Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE trial of sildenafil added to therapeutic hypothermia in term neonates with hypoxic-ischemic encephalopathy
2023-508928-35-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypoxic-ischemic encephalopathy (HIE) comparing Sildenafil + therapeutic hypothermia with Placebo + therapeutic hypothermia (2 arms). Planned start Nov 2024; status: authorised.
02
Drugs
sildenafil
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on 2023-508928-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508928-35-00.